By Bhanvi Satija and Maggie Fick

Summary:

– Pfizer ‘s recent U.S. drug pricing deal spurs speculation on Lilly and AstraZeneca .

– Both companies are making significant U.S. investments, including new Virginia facilities.

– Analysts note Trump’s administration is actively engaging pharma CEOs on price reductions.

LONDON — Wall Street is looking to U.S. drugmaker Eli Lilly and Anglo-Swedish rival AstraZeneca as the potential next in line after Pfizer struck a deal with Donald Trump ‘s administration to lower drug prices last week.

Reuters spoke to seven healthcare analysts and investors. Four said Lilly could be next to make a deal, while three pointed to AstraZeneca . Others mentioned Merck , AbbVie , Regeneron and Bristol-Myers Squibb.

Reuters coul

See Full Page